바이오테크 보도자료
-
- Arthur D. Little Promotes Nine New Partners Across Global Offices
- Arthur D. Little (ADL) today announced the promotion of nine of its consultants to the rank of Partner across a number of its global offices. Each new Partner has demonstrated their commitment to ADL, passion and dedication to the industries and c...
- 2022년 03월 16일
-
- Encina Announces $55 Million of Committed Financing Supported by IMM Investment Global Limited
- Encina Development Group (“Encina” or the “Company”), a producer of circular chemicals from waste materials, announced today that it has secured a total of $55 Million of equity capital which included participation from institutional investors IMM...
- 2022년 03월 15일
-
- Join KOREA PACK & ICPI WEEK 2022 to Be Held June 14 - 17, KINTEX, Korea!
- KOREA PACK and ICPI WEEK (Int’l Cosmetic and Pharmaceutical Industry Week), the largest packaging, cosmetic and pharmaceutical exhibition in Korea, will be held at KINTEX from June 14th to 17th as hybrid events hosted by Kyungyon Exhibition Corp. ...
- 2022년 03월 14일
-
- Blood Cancer Biomarkers Market: Why Is It Expected That The Asian Market Will Outperform Others, Detailed Study By Fact.MR
- According to Fact.MR’s Study, the cancer biomarkers market revenue is anticipated to surpass US$ 33 Bn by 2031, representing a 3x increase from 2020. Presently, the market is valued at a little above US$ 11 Bn. The increasing prevalence of debilit...
- 2022년 03월 11일
-
- Alvotech Resolves U.S. Patent and Trade Secret Disputes with AbbVie, Securing U.S. Rights for Alvotech’s Proposed High-Concentration Biosimilar (AVT02) for Humira®
- Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, announced today that is has executed a U.S. settlement agreement with AbbVie ...
- 2022년 03월 10일
-
- Sodium Lactate Market Latest Trends, Demand, Growth, Opportunities & Outlook Till 2031: Future Market Insights
- Sodium lactate market revenue totaled US$ 158.7 Mn for 2021, according to a study by Future Market Insights (FMI). The overall sodium lactate sales are expected to reach US$ 368.3 Mn by 2031, growing at a CAGR of 8.8% for 2021 - 2031. Sodium lacta...
- 2022년 03월 10일
-
- ANANDA Scientific and NYU Grossman School of Medicine Announce First Patient Enrolled in the Clinical Trial for Opioid Sparing in Participants with Radiculopathic Pain
- ANANDA Scientific Inc., a biotech pharmaceutical company, and NYU Grossman School of Medicine today announced that the first patient has been enrolled in a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol in ...
- 2022년 03월 09일
-
- Publication of definitive Interim Result for Vifor Pharma tender offer: CSL Behring AG declares offer successful
- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today announced the definitive notice of the Interim Res...
- 2022년 03월 08일
-
- Schneider Electric announces promising start of its Sustainability Impact program
- Schneider Electric, the leader in the digital transformation of energy management and automation, announced today the progress made on its Schneider Sustainability Impact (SSI) program at the end of Q4 2021, marking the end of this ambitious progr...
- 2022년 03월 08일
-
- GI Innovation Forms Co-representative System by Recruiting CEO Byung-Geon Rhee, Former CEO of GC Pharma and SCM Lifescience
- GI Innovation, a new innovative drug development company, announced on March 4th that it has recruited Chief Executive Officer (CEO) and Chairman, Byung-Geon Rhee, former CEO of GC Pharma, SCM Lifescience Corp. Byung-Geon Rhee, CEO received a chem...
- 2022년 03월 07일
-
- Publication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percent
- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today announced the provisional notice of the interim re...
- 2022년 03월 03일
-
- Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
- Takeda (TSE:4502/NYSE:TAK) today presented four abstracts including interim real-world data from the observational Phase 4 EMPOWER study of TAKHZYRO® (lanadelumab) as a treatment for people with Hereditary Angioedema (HAE) Type I or II in North Am...
- 2022년 03월 02일
전시회
